Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia-Reference-Cited by-同舟云学术

Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia

Published:2023-12 Issue: Volume:31 Page:100751
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Boucher Justin C.,Shrestha Bishwas,Vishwasrao Paresh,Leick Mark,Cervantes Estelle V.,Ghafoor Tayyebb,Reid Kayla,Spitler Kristen,Yu Bin,Betts Brian C.,Guevara-Patino Jose A.,Maus Marcela V.,Davila Marco L.^ORCID

Funder

Moffitt Cancer Center

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference52 articles.

1. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia;Jan;Sci. Transl Med.,2012

2. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia;Shlush;Nature,2014

3. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach;Cornelissen;Nat. Rev. Clin. Oncol.,2012

4. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial;Burnett;Br. J. Haematol.,2002

5. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy;Zeiser;N. Engl. J. Med.,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR’TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment;Molecular Therapy: Oncology;2024-06